Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Cannabinoid type-1 (CB₁) receptor antagonists were investigated for obesity and addiction but faced withdrawal due to psychiatric side effects like anxiety and depression.
• Genomic studies link variants in the CB₁ receptor gene (CNR1) and serotonin transporter gene (SLC6A4) to anxiety and depression risk.

Purpose of the Study:

• To review endocannabinoid signaling in anxiety and depression.
• To identify the serotonergic system as a key mediator of CB₁ antagonist side effects.
• To propose genetic screening for safe use of CB₁ receptor antagonists.

Main Methods:

• Review of existing literature on endocannabinoid signaling, CB₁ receptor antagonists, and psychiatric side effects.
• Analysis of genomic studies implicating CNR1 and SLC6A4 variants in anxiety and depression.
• Proposal for a risk stratification model combining genetic, phenotypic, and environmental factors.

Main Results:

• Endocannabinoid signaling pathways are implicated in anxiety and depression.
• The serotonergic system is a likely mediator of CB₁ antagonist-induced psychiatric side effects.
• Polymorphisms in CNR1, SLC6A4, and CYP 450 enzymes may identify individuals who can safely use CB₁ antagonists.

Conclusions:

• Combining genomic screening with phenotypic and environmental risk factors can facilitate the safe use of CB₁ receptor antagonists.
• Genetic testing can identify individuals who may benefit from CB₁ antagonist treatment without adverse psychiatric effects.
• This approach holds promise for managing obesity and addiction while mitigating risks.